


A woman in a surgical cap and gown is in the foreground, looking towards the camera. In the background, other medical professionals in scrubs and masks are working in an operating room. The entire image has a blue tint.


Corporate Presentation

Group Communications

ESSENTIAL HISTORY

More than 100 years of experience in innovation and development for the well-being of patients.

ESSENTIAL DATES



ESSENTIAL: WORKING FOR LIFE

Aguettant is a fully integrated pharmaceutical company developing innovative specialty injectable medicines dedicated to hospital specialists.

2024/2025 AT A GLANCE

1903

since its creation in 1903 :
AGUETTANT is an independent,
family-owned company



270

€270 million of global turnover,
EBITDA CAGR over the last 5 years:
7 %



+1200

employees
all over the world



5

sites in France:
4 pharmaceutical sites
2 logistics platforms

3 production
sites



2 logistics
platforms



10

subsidiaries in Europe
and Asia



90

direct and indirect presence
in more than 90 countries



1000+

marketing
authorisations all
over the world



75

medicines for hospitals:
anaesthesia, critical care,
neurology, paediatrics



AN INTEGRATED COMPANY – from R&D to commercialisation

A strong know-how and growing track record in injectable medicines and combination products. Aguettant is recognized as a key European player in “SPECIALTY INJECTABLE PHARMACEUTICALS”



OUR ESSENTIAL MISSION



Guillaume d'ARCY
Chairman of the Executive Board

« **A family-owned company** for six generations, the Aguettant Group continues its **mission** with determination: to provide healthcare professionals around the world with the essential medicines they need to treat **patients**.

As experts in injectable medicines, we oversee every stage of their lifecycle: from development and industrialisation to international commercialisation.

At every step, more than 1,200 employees combine their expertise to **innovate**, enhance the quality and usability of our products, and make them accessible to a growing number of **hospitals** and healthcare centers.

Our impact is tangible: every solution we develop helps **save lives** and **improve care pathways**.

Our mindset is reflected in our core **values**: *initiative, integrity, high standards, and commitment*.


We pursue a clear **ambition**, focused on what truly matters: contributing to a more efficient healthcare system, while placing sustainability at the heart of our development. »

OUR THERAPEUTIC AREAS


■ 5 CORE THERAPEUTIC AREAS



Locoregional anaesthesia
Patient Blood management
Emergency and critical care
Surgery



Pain Management



Trace Elements




Parkinson's Disease
Epilepsy
Spasticity



Solution/Perfusion

A DEDICATED HOSPITAL PARTNER, SERVING HCPs AT ALL STAGES OF THE INPATIENT JOURNEY

INPATIENT Initial hospital prescription



ESSENTIAL: INNOVATING FOR BETTER CARE

We design the solutions of the future by innovating
for safer medical practices and making the
everyday work of healthcare professionals easier.

R&D – PRODUCT SAFETY

15

active patents



9

patents in process



5%

of sales
invested



31

Employees dedicated
to this activity




Laboratoire Aguettant calls on its dual competencies :

- THE PHARMACEUTICAL DEVELOPMENT OF INJECTABLE FORMULAS
 - stabilisation of fragile active principles and unstable mixes in solutions
 - preservative-free formulations
 - microdose formulations
- DESIGN AND DEVELOPMENT OF INNOVATIVE MEANS OF ADMINISTRATION
 - pre-filled syringes
 - injection pens

A dual competence that enhances safe administration and reduces errors, while improving patient care and autonomy

AGUETTANT INNOVATION



ESSENTIAL: A SUSTAINABLE FUTURE

Management and employees take part in a collective approach to improve environmental, economic and social drivers.

SUSTAINABLE BUSINESS



In March 2025, Aguettant was awarded a Silver medal by **EcoVadis** for its Corporate Social Responsibility (CSR) performance, based on the following 4 themes:



Aguettant scored better than industry average in all 4 categories.



In 2024, Laboratoire Aguettant **obtained ISO 14001 (Environmental Management System) certification** for all its sites.




Launched in 2017 by the Minister of the Economy, Finance and Recovery, Bruno Le Maire, **La French Fab federates the industrial ecosystem throughout France**. It aims to share responsible best practices and industrial know-how to connect talents towards more inclusive and competitive jobs in a protected environment.

SUSTAINABLE BUSINESS : environment

Concrete actions are carried out with strong visible impacts both in terms of resource optimisation and in terms of energy performance.

- In **2020**, Aguettant carried out **its 1st assessment** of greenhouse gas emissions for **scopes 1 and 2** in **France**. Concrete actions have led to a **20% reduction in GHG emissions**.
- In **2024**, Aguettant carried out an **international assessment** of its greenhouse gas emissions for **scopes 1, 2 and 3**. An action plan is currently under consideration.



ESSENTIAL: BUILDING TRUST

As an integrated pharmaceutical company,
we make the reliability of our value chain
our top priority.

FRENCH RELANCE RECOVERY PLAN



IN 2020, AGUETTANT WAS SELECTED BY THE FRENCH PUBLIC AUTHORITIES FOR ITS INDUSTRIAL PROJECT, AS PART OF THE NATIONAL COVID-19 RECOVERY PLAN.

Aguettant is engaged in a continuous investment in innovation and development of its industrial capacities.

This ambitious approach serves both the strategic ambition of the company and the aspirations of the public authorities to keep French businesses in France.



OUR ESTABLISHMENTS IN FRANCE



**LYON GERLAND
(Rhône)**

**GMP (ANSM) site, ISO 13485-
certified (GMED) and ISO
14001.**

Production of medicines with high medical value: formulation, filling and packaging in a controlled-atmosphere zone. Lyon is also home to Aguettant's Head Office.



**SAINT-FONS
(Rhône)**

**GDP (ANSM) site, ISO 13485-
certified (GMED) and ISO
14001.**

The logistics platform and customer services are totally integrated, from the confirmation of the purchase order to the delivery of the goods.



**CHAMPAGNE
(Ardèche)**

**GMP (ANSM) site, ISO 13485-
certified (GMED) and ISO
14001.**

Production of high volumes of sterile products in plastic: polypropylene ampoules, pre-filled syringes and bottles, as well as polyethylene bottles.



**MOUVAUX
(North)**

GMP (ANSM) site.

Production of sterile 50ml - 2 litre infusion bags and logistic platform.

OUR PRODUCTION CAPACITIES

3

INDUSTRIAL SITES

330 million
medicines per year



2

LOGISTICS PLATFORMS

International
capacity



STOCKAGE
30,000 pallets



PREPARATION
150,000
pallets per year

Our Industrial Know How

11

Product Presentations



PLASTIC AMPOULE



GLASS AMPOULE



GLASS
VIAL



CREAM
TUBE




PLASTIC PRE-
FILLED SYRINGE



AUTO
INJECTOR
PEN



PLASTIC
CONTAINER
AND BOTTLE



ADHESIVE SKIN
DRESSING



INFUSION
BAG



CARTRIDGE




SUBLINGUAL
TABLET

ESSENTIAL: ACTING GLOBALLY

Collaborating with our partners,
working with healthcare professionals,
improving the quality of life of patients
make our employees proud and committed.

A DIRECT AND INDIRECT PRESENCE

90 COUNTRIES, AN INTERNATIONAL IMPACT



AGUETTANT ESSENTIAL MEDICINES

**Find out more:
www.aguettant-corporate.com**

November 2025, published by Global Communications